帕罗西汀介导的GRK2抑制对前壁心肌梗死患者左室重构的影响:随机临床试验
主要终点为基线与12周心脏磁共振评估的LVEF改善差异,结果显示两组间无显著差异;晚期钆增强百分比在实验组下降更明显。
要点
- 帕罗西汀20mg/日治疗12周未改善急性前壁心梗后LVEF恢复。
- 晚期钆增强百分比在帕罗西汀组下降更显著,提示可能减少瘢痕。
- 左室舒张末期和收缩末期容积变化两组间无显著差异。
核心结论
- 在急性前壁心肌梗死患者中,帕罗西汀治疗12周与安慰剂相比未改善LVEF恢复。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,在瑞士伯尔尼大学医院开展。
- 38例患者完成了基线和12周心脏磁共振成像评估。
临床怎么用
- 对于急性前壁心肌梗死后LVEF≤45%的患者,帕罗西汀不应以改善LVEF为目的使用。
- 晚期钆增强的改善提示可能减少心肌瘢痕,但需进一步研究验证。
局限性
- 样本量较小,仅38例完成主要终点影像评估。
- 仅纳入前壁ST段抬高型心肌梗死且LVEF≤45%的患者,结果外推受限。
- 随访时间仅12周,长期效应未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Left ventricular remodeling following acute myocardial infarction results in progressive myocardial dysfunction and adversely affects prognosis. OBJECTIVE: To investigate the efficacy of paroxetine-mediated G-protein-coupled receptor kinase 2 inhibition to mitigate adverse left ventricular remodeling in patients presenting with acute myocardial infarction. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial was conducted at Bern University Hospital, Bern, Switzerland. Patients with acute anterior ST-segment elevation myocardial infarction with left ventricular ejection fraction (LVEF) of 45% or less were randomly allocated to 2 study arms between October 26, 2017, and September 21, 2020. INTERVENTIONS: Patients in the experimental arm received 20 mg of paroxetine daily; patients in the control group received a placebo daily. Both treatments were provided for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the difference in patient-level improvement of LVEF between baseline and 12 weeks as assessed by cardiac magnetic resonance tomography. Secondary end points were changes in left ventricular dimensions and late gadolinium enhancement between baseline and follow-up. RESULTS: Fifty patients (mean [SD] age, 62 [13] years; 41 men [82%]) with acute anterior myocardial infarction were randomly allocated to paroxetine or placebo, of whom 38 patients underwent cardiac magnetic resonance imaging both at baseline and 12 weeks. There was no difference in recovery of LVEF between the experimental group (mean [SD] change, 4.0% [7.0%]) and the control group (mean [SD] change, 6.3% [6.3%]; mean difference, -2.4% [95% CI, -6.8% to 2.1%]; P = .29) or changes in left ventricular end-diastolic volume (mean difference, 13.4 [95% CI, -12.3 to 39.0] mL; P = .30) and end-systolic volume (mean difference, 11.4 [95% CI, -3.6 to 26.4] mL; P = .13). Late gadolinium enhancement as a percentage of the total left ventricular mass decreased to a larger extent in the experimental group (mean [SD], -13.6% [12.9%]) compared with the control group (mean [SD], -4.5% [9.5%]; mean difference, -9.1% [95% CI, -16.6% to -1.6%]; P = .02). CONCLUSIONS AND RELEVANCE: In this trial, treatment with paroxetine did not improve LVEF after myocardial infarction compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03274752.
引用
- Pilgrim T, Vollenbroich R, Deckarm S, et al. Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 34259826. doi:10.1001/jamacardio.2021.2247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。